HNSCC | Nano Publications

2019 – ASCO – Phase I NBTXR3 in elderly/frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

New therapeutic approaches are needed for elderly or frail head and neck squamous cell carcinoma (HNSCC) patients (pts) ineligible for standard of care treatment. NBTXR3, a crystalline solution of hafnium oxide nanoparticles may represent such an option. Injected intratumorally, NBTXR3 enters tumor cells and yields an increased cell-localized energy deposit upon exposure to radiotherapy (RT), leading to increased tumor cell death compared to the same dose of RT alone. […]

Continuer la lecture…

2019 – AHNS – Phase I/II NBTXR3 in combination with anti-PD-1

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Preoperative radiotherapy (RT) is an option for a subset of patients with locally advanced primary or relapsed tumors. Yet, its impact on efficacy in terms of pathological response is limited, highlighting the need for novel multimodal therapies aimed at local control with low toxicity. NBTXR3 is made of hafnium oxide nanoparticles which, injected intratumorally (IT) and activated by ionizing radiation, yield a tumor-localized high energy deposit and increase cell death compared to the same dose of RT alone. […]

Continuer la lecture…

2019 – ASCO-SITC – NBTXR3 with anti-PD-1 in advanced HNSCC or NSCLC

Abstracts, Donnée clinique de NBTXR3, Poumon, Tête & Cou

Despite proven efficacy, a limited number of patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or metastatic non-small cell lung cancer (NSCLC) benefit from anti-PD-1 treatment. Indeed, most pts do not respond to initial therapy due to intrinsic re-sistance to checkpoint inhibition. There is thus an important unmet medical need for a curative treatment in these pts and converting the local immune microenvironment to a “hot” phenotype may help to overcome therapeutic resistance. […]

Continuer la lecture…

2019 – ICHNO – Phase I/II NBTXR3 in HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Hafnium oxide nanoparticles, NBTXR3, were developed to augment tumor-localized high energy deposit once activated by ionizing radiation such as Intensity Modulated Radiation Therapy (IMRT) and thus to increase tumor cell death compared to the same dose of radiation. NBTXR3 is characterized by a single intratumoral (IT) administration and fits into standard radiotherapy schedule with no change in patient’s care pathway, treatment protocol or equipment. […]

Continuer la lecture…

2018 – OncoRad – NBXTR3 in HNSCC and NSCLC with anti-PD1

Abstracts, Donnée clinique de NBTXR3, Poumon, Tête & Cou

Recent clinical studies have demonstrated the efficacy of anti-PD-1 in recurrent/metastatic HNSCC and upfront metastatic NSCLC patients. However, most patients with recurrent/metastatic HNSCC demon-strate innate (primary) resistance to checkpoint inhibition and do not respond to initial therapy and only a subset of metastatic HNSCC/NSCLC patients benefits from this treatment. […]

Continuer la lecture…

2018 – SIOG – NBTXR3 In Elderly With HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Compared to younger individuals, elderly patients with head and neck squamous cell carcinoma (HNSCC) have limited therapeutic options. Despite representing approximately 47% of the affected population with an increasing incidence, older patients are underrepresented from HNSCC prospective clinical trials further limiting their therapeutic options. […]

Continuer la lecture…

2018 – ASTRO 2018 – NBTXR3 in elderly HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

As the incidence of head and neck squamous cell carcinoma (HNSCC) increases with age, elderly patients represent 25% of the affected population with an expected increase in the next 20 years. Being more vulnerable to treatment-induced toxicities, the elderly cannot be treated like younger patients, hence requiring innovative therapies. […]

Continuer la lecture…

2018 – ESMO 2018 – NBTXR3 in elderly HNSCC

Abstracts, Donnée clinique de NBTXR3, Foie

Elderly patients (pts) with head and neck squamous cell carcinoma (HNSCC) represent 25% of the affected population. They are not always eligible to the same treatment of younger pts, thus require new therapies. NBTXR3, injectable hafnium oxide nanoparticles activated by radiotherapy (RT), was developed to increase the local deposit of energy within the tumor. […]

Continuer la lecture…

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continuer la lecture…

2018 – ECHNO 2018 – NBTXR3 for elderly and frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau. […]

Continuer la lecture…